Table 4.

Patient Characteristics and 6-Year Probability of MMR, 4-Log Reduction in Transcript Levels, and CMR at Diagnosis

Variable at Diagnosis	No. of Patients	Response
		MMR		4-Log Reduction		CMR
		%	P	%	P	%	P
Sex
Male	49	68.1	.45	53.8	.2	26.9	.29
Female	38	70.3		59.5		39.1
Age, years
≤ 45	42	66.4	.056	44.2	.07	21.0	.052
> 45	45	80.2		65.8		46.1
RR		1.020	.06	1.013	.27	1.015	.15
Sokal risk group			.49		.98		.36
Low	33	77.8		67.8		54.1
Intermediate	32	69.4		47.0		31.1
High	22	61.3		47.1		24.8
Hemoglobin, g/L
≤ 115	40	59.2	.036	39.5	.03	14.7	.011
> 115	47	80.7		69.1		47.6
RR		1.186	.012	1.323	.01	1.209	.07
Leukocytes, × 109/L
≤ 140	44	78.8	.012	56.7	.022	35.4	.017
> 140	43	63.1		37.6		28.1
RR		0.996	.008	0.996	.015	.996	.11
BCR-ABL1 transcript type
e14a2	40	78.1	.05	56.9	.024	34.1	.29
e13a2	33	63.5		35.7		20.3
e13a2 and e14a2	14	76.5		57.6		38.5
BCR-ABL1/ABL1 ratio, %
≤ 100	44	71.4	.25	53.0	.038	32.7	.1
> 100	43	52.6		26.6		8.4
RR		.996	.44	.971	.002	.979	.13
hOCT1 transcript level
≤ 0.16	30	55.2	< .001	42.0	.01	16.6	.02
> 0.16	30	81.4		64.8		45.3
RR		2.199	< .001	1.990	.001	1.665	.04
MDR1 polymorphism
C/C	75	71.1	.9	57.8	.35	30.8	.8
T/C	12	68.7		36.5		37.1

Abbreviations: MMR, major molecular response; CMR, complete molecular response; RR, relative risk; hOCT1, human organic cation transporter-1; MDR1, multidrug resistance gene-1.

^*Samples were not available in 27 patients. For this reason, we repeated the multivariate analysis excluding this variable. The adherence rate and WBC were the only independent predictors for the achievement of MMR; adherence rate was the only independent predictor for the achievement of a 4-log reduction and CMR. In three patients, the trough plasma level was not available.